Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg
Anne Katrin Berger, Stefanie Zschaebitz, Dirk Jäger, Georg-Martin Haag, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany
Christine Komander, NCT Clinical Cancer Registry, German Cancer Research Center, 69120 Heidelberg, Germany
Author contributions: Berger AK participated in study concepts and design, data acquisition, data analysis and interpretation, manuscript preparation and editing; Haag GM participated in data analysis and interpretation, manuscript preparation, quality control of data and algorithms and statistical analysis; Komander C participated in data acquisition and manuscript preparation; Jäger D and Zschaebitz S participated in data analysis and interpretation and manuscript preparation and review; all authors read and approved the final manuscript.
Supported by Zentrum für Geriatrische Onkologie und Biologie in der Metropolregion Rhein Neckar (ZOBEL).
Ethics approval: The study was approved by the local Ethics Committee (Ethics Committee University of Heidelberg; S-335/2014, 28.07.2014).
Informed consent: According to local ethics policy for retrospective analysis of own anonymized clinical data, IC was not obtained.
Conflict-of-interest: The authors state that there is no conflict of interest to disclose.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Anne Katrin Berger, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. firstname.lastname@example.org
Telephone: +49-6221-567229 Fax: +49-6221-567225
Received: October 8, 2014
Peer-review started: October 9, 2014
First decision: November 14, 2014
Revised: December 3, 2014
Accepted: December 19, 2014
Article in press: December 22, 2014
Published online: April 28, 2015